R 911
Alternative Names: R-911Latest Information Update: 28 Dec 2021
At a glance
- Originator Radikal Therapeutics
- Class Peptides
- Mechanism of Action Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute lung injury; Bronchopulmonary dysplasia; Kidney disorders
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Acute-lung-injury in USA (IV)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Kidney-disorders in USA (IV)
- 29 Nov 2019 Preclinical development for Kidney disorder is ongoing in USA (IV) (Radikal Therapeutics pipeline, November 2019)